Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ACG Clinical Guideline: Management of Crohn's Disease in Adults
Gary R. Lichtenstein, Edward V. Loftus, Kim L. Isaacs, et al.
The American Journal of Gastroenterology (2018) Vol. 113, Iss. 4, pp. 481-517
Closed Access | Times Cited: 1143

Showing 1-25 of 1143 citing articles:

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Joana Torres, Stefanos Bonovas, Glen Doherty, et al.
Journal of Crohn s and Colitis (2019) Vol. 14, Iss. 1, pp. 4-22
Open Access | Times Cited: 1107
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
Michel Adamina, Stefanos Bonovas, Tim Raine, et al.
Journal of Crohn s and Colitis (2019) Vol. 14, Iss. 2, pp. 155-168
Open Access | Times Cited: 990
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry
Erica J. Brenner, Ryan C. Ungaro, Richard B. Gearry, et al.
Gastroenterology (2020) Vol. 159, Iss. 2, pp. 481-491.e3
Open Access | Times Cited: 668
The microbiome and inflammatory bowel disease
Kerri Glassner, Bincy Abraham, Eamonn M.M. Quigley
Journal of Allergy and Clinical Immunology (2020) Vol. 145, Iss. 1, pp. 16-27
Open Access | Times Cited: 658
Evidence-based clinical practice guidelines for inflammatory bowel disease
Katsuyoshi Matsuoka, Taku Kobayashi, Fumiaki Ueno, et al.
Journal of Gastroenterology (2018) Vol. 53, Iss. 3, pp. 305-353
Open Access | Times Cited: 630
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward, Atul Deodhar, Lianne S. Gensler, et al.
Arthritis Care & Research (2019) Vol. 71, Iss. 10, pp. 1285-1299
Open Access | Times Cited: 532
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward, Atul Deodhar, Lianne S. Gensler, et al.
Arthritis & Rheumatology (2019) Vol. 71, Iss. 10, pp. 1599-1613
Open Access | Times Cited: 527
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, et al.
Journal of Gastroenterology (2021) Vol. 56, Iss. 6, pp. 489-526
Open Access | Times Cited: 354
Effect of IBD medications on COVID-19 outcomes: results from an international registry
Ryan C. Ungaro, Erica J. Brenner, Richard B. Gearry, et al.
Gut (2020) Vol. 70, Iss. 4, pp. 725-732
Open Access | Times Cited: 274
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
William J. Sandborn, Brian G. Feagan, Edward V. Loftus, et al.
Gastroenterology (2020) Vol. 158, Iss. 8, pp. 2123-2138.e8
Open Access | Times Cited: 249
An expert consensus framework for asthma remission as a treatment goal
Andrew Menzies‐Gow, Mona Bafadhel, William W. Busse, et al.
Journal of Allergy and Clinical Immunology (2019) Vol. 145, Iss. 3, pp. 757-765
Open Access | Times Cited: 247
Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study
Bing Zhang, Hohui E. Wang, Ya‐Mei Bai, et al.
Gut (2020) Vol. 70, Iss. 1, pp. 85-91
Closed Access | Times Cited: 236
Management of Crohn Disease
Kelly C. Cushing, Peter Higgins
JAMA (2021) Vol. 325, Iss. 1, pp. 69-69
Open Access | Times Cited: 234
Anti-TNF Therapy in Crohn’s Disease
S Adegbola, Kapil Sahnan, Janindra Warusavitarne, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 8, pp. 2244-2244
Open Access | Times Cited: 226
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
Marc Ferrante, Remo Panaccione, Filip Baert, et al.
The Lancet (2022) Vol. 399, Iss. 10340, pp. 2031-2046
Closed Access | Times Cited: 208
The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management
Jane Fletcher, Sheldon C. Cooper, Subrata Ghosh, et al.
Nutrients (2019) Vol. 11, Iss. 5, pp. 1019-1019
Open Access | Times Cited: 187
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Bruce E. Sands, Peter M. Irving, Timothy Hoops, et al.
The Lancet (2022) Vol. 399, Iss. 10342, pp. 2200-2211
Closed Access | Times Cited: 183
The Role of Early Biologic Therapy in Inflammatory Bowel Disease
Dana Berg, Jean‐Frédéric Colombel, Ryan C. Ungaro
Inflammatory Bowel Diseases (2019) Vol. 25, Iss. 12, pp. 1896-1905
Open Access | Times Cited: 172
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
Stefan Schreiber, Shomron Ben‐Horin, Jarosław Leszczyszyn, et al.
Gastroenterology (2021) Vol. 160, Iss. 7, pp. 2340-2353
Closed Access | Times Cited: 171
Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User’s Guide for Adult and Pediatric Gastroenterologists
Manasi Agrawal, Elizabeth Spencer, Jean‐Frédéric Colombel, et al.
Gastroenterology (2021) Vol. 161, Iss. 1, pp. 47-65
Open Access | Times Cited: 159
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial
Henit Yanai, Arie Levine, Ayal Hirsch, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 7, Iss. 1, pp. 49-59
Closed Access | Times Cited: 143
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial
Séverine Vermeire, Geert R. DʼHaens, Filip Baert, et al.
Journal of Crohn s and Colitis (2021) Vol. 16, Iss. 1, pp. 27-38
Open Access | Times Cited: 129
Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Waseem Ahmed, Jonathan Galati, Anand Kumar, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 3, pp. e361-e379
Closed Access | Times Cited: 123
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab
Andrew Menzies‐Gow, Flavia Hoyte, David Price, et al.
Advances in Therapy (2022) Vol. 39, Iss. 5, pp. 2065-2084
Open Access | Times Cited: 88
Inflammatory Bowel Disease
Lia Pierson Bruner, Anna Marie White, Siobhan Proksell
Primary Care Clinics in Office Practice (2023) Vol. 50, Iss. 3, pp. 411-427
Closed Access | Times Cited: 84
Page 1 - Next Page

Scroll to top